Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy.

Seya, Tsukasa; Takeda, Yohei; Takashima, Ken; Yoshida, Sumito; Azuma, Masahiro; Matsumoto, Misako

Seya, Tsukasa; Takeda, Yohei; Takashima, Ken; Yoshida, Sumito; Azuma, Masahiro; Matsumoto, Misako.

Afiliación

Seya T; Department of Vaccine Immunology, Hokkaido University Graduate School of Medicine.
Takeda Y; Department of Vaccine Immunology, Hokkaido University Graduate School of Medicine.
Takashima K; Department of Vaccine Immunology, Hokkaido University Graduate School of Medicine.
Yoshida S; Department of Vaccine Immunology, Hokkaido University Graduate School of Medicine.
Azuma M; Department of Vaccine Immunology, Hokkaido University Graduate School of Medicine.
Matsumoto M; Department of Vaccine Immunology, Hokkaido University Graduate School of Medicine.

Proc Jpn Acad Ser B Phys Biol Sci ; 94(3): 153-160, 2018.

Article en En | MEDLINE | ID: mdl-29526974

Asunto(s)

Adyuvantes Inmunológicos/uso terapéutico; Células Dendríticas/inmunología; Inmunoterapia/métodos; Neoplasias/inmunología; Neoplasias/terapia; Animales; Humanos

Palabras clave

PD-1/L1 blockade; TLR3; adjuvant; cancer immunotherapy; polyI:C

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Células Dendríticas / Adyuvantes Inmunológicos / Inmunoterapia / Neoplasias Límite: Animals / Humans Idioma: En Revista: Proc Jpn Acad Ser B Phys Biol Sci Asunto de la revista: BIOLOGIA / FISIOLOGIA Año: 2018 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google